docetaxel + paclitaxel + zoledronic acid

- **Docetaxel** and **paclitaxel** are both taxane-class chemotherapeutic agents that act as microtubule stabilizers, inhibiting cell division by promoting the assembly and stabilization of microtubules, thereby arresting cells in the mitotic phase. Both are widely used in the treatment of various cancers, including breast cancer and non-small-cell lung cancer. While they share a similar mechanism, their pharmacokinetic profiles and toxicity spectra differ slightly. - **Zoledronic acid** is a nitrogen-containing bisphosphonate that inhibits osteoclast-mediated bone resorption by blocking farnesyl pyrophosphate synthase in the mevalonate pathway. It is primarily used to prevent skeletal-related events (SREs) in patients with bone metastases from solid tumors. The rationale for combining these drugs lies in their complementary mechanisms—taxanes provide direct cytotoxicity against tumor cells, while zoledronic acid helps manage bone metastases and may have additive or synergistic antitumor effects when combined with chemotherapy[1][2][7]. This combination has been explored particularly for cancers with high risk or presence of bone metastases (e.g., metastatic breast cancer, prostate cancer), though most clinical studies focus on two-drug combinations rather than all three together.